Urinary Profiles of the Endogenous Steroids in Pre-Menopausal Women with Uterine Leiomyoma
![]() |
Jung, Byung-Hwa
(Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology)
Bai, Sang-Wook (Department of Obstetrics and Gynecology, College of Medicine, Yonsei University) Chung, Bong-Chul (Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) Kim, Sei-Kwang (Department of Obstetrics and Gynecology, College of Medicine, Yonsei University) Park, Ki-Hyun (Department of Obstetrics and Gynecology, College of Medicine, Yonsei University) |
1 | Andersen J, Barbieri RL. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Investig 1995;2: 663-72 DOI ScienceOn |
2 | Sudan O, Ginath S, Sofer D, Rotmensch S, Debby A, Glezerman M, Zakut H. The role of tamoxifen in the treatment of sysptomatic uterine leiomyomata -a pilot study. Eur J Obstet Gynecol Reprod Biol 2001; 96: 183-6 DOI ScienceOn |
3 | Cirkel U, Ochs H, Roehl A, Schneider HPG. Estrogen and progesterone receptor content of enucleated uterine myoma after lutenizing hormone-releasing hormone. Acta Obstet Gynecol Scand 1994; 73: 328-32 DOI ScienceOn |
4 | Potgieter HC, Magagane F, Bester MJ. Oestrogen and progesterone receptor status and PgR/ER ratios in normal and myomatous human myometrium. East Afr Med J 1995; 72: 510-4 PUBMED |
5 | Wu J, Cheng Y. Research on the relationship between estrogen receptor, progesterone receptor, cell proliferation associated antigen in uterine leiomyoma and nuclear body density of myoma, serum reproductive hormone oncentration. Chung-Hua FU Chan Ko Tsa Chih 1995; 30: 603-7 |
6 | Lee SH, Yang YJ, Kim TW, Paeng KJ, Chung BC. Urinary profiling of endogenous estrogens using GC/MS. J Kor Chem Soc 1997; 41: 186-97 |
7 | Sudan O, van Iddekinge B, van Gelderen CJ, Savage N, Becker PJ, van der Walt LA, Robinson M. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 1987; 24: 263-7 DOI |
8 | Berek JS, Adashi EY, Hillard RA. Novak's Gynecology 12th rev. ed. Baltimore: Williams & Wilkins. 1996: 149 |
9 |
Pollow K, Sinnecker G, Boquai E, Pollow B. In vitro conversion of estradiol- |
10 | Brandon DD, Erickson TE, Keenan EJ, Strawn EY, Novy MJ, Burry KA, Warner C, Clinton CM. Estrogenreceptor gene expression in human uterine eiomyomata. J Clin Endocrinol Metab 1995; 80: 1876-81 DOI |
11 | Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT. Fibroid and myometrial steroid receptors in women treated with the gonadotropin-releasing hor- mone agonist leuprolide acetate. Fertil Stril 1990; 53:1018-23 DOI |
12 | Friedman AJ, Barbieri RL, Doubliet PM, Fine C, Schiff I. A randomized, double-blind trial of gonadotropin-releasing hormone gonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49:404-9 DOI PUBMED |
13 | Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropinreleasing hormone agonist: The estrogen threshold hypothesis. Am J Obstet Gynecol 1990; 63: 1114-9 |
14 | Englund K, Blanck A, Gustavasson I, Lundkvist U, Sjoblom P, Norgren A, Nindblom B. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropinreleasing hormone treatment. J Clin Endocrinol Metab 1998; 83: 4092-6 DOI |
15 | Jasonni VM, Bonavia M, Lodi S, Preti S, Bulletti C, Flamigni C. Androstenedione metabolism in human uterine tissue: endometrium, myometrium and leiomyoma. J Steroid Biochem 1982; 17: 547-51 DOI ScienceOn |
16 | Andreyko JL, Blummenfeld Z, Marshall LA, Monroe SE, Hricak H, Jaffé RB. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. Am J Obstet Gynecol 1988;159: 903-10 DOI |
17 | Otubu JA, Buttram VC, Besch NF, Besch PK. Unconjugated steroids in leiomyomas and tumorbearing myometrium. Am J Obstet Gynecol 1982; 143: 130-3 DOI PUBMED |
18 | Yamamoto T, Fukuoka M, Fujimoto Y, Kitawaki J, Nakakosh M, Yoshihama M, Okada M. Inhibitory effect of a new androstenedione derivative, 14ahydroxy-4-androstene-3, 6, 17-trione (14a-OHAT) on aromatase activity of human uterine tumors. J Steroid Biochem 1990; 36: 517-20 DOI ScienceOn |
19 | Ichibura T, Kawamura N, Ito F, Shibata S, Minakuchi-Minakuchi K, Tsujimura A, Umesaki N, Ogita S. Correlation between the growth of uterine leiomyomata and estrogen and progesterone receptor content in needle biopsy specimens. Fertil Steril 1998; 70: 967-71 DOI ScienceOn |
20 | Buttram VC JR, Reiter RC. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981; 36: 433-45 DOI PUBMED |
21 | Lee SH, Choi MH, Kim TW, Chung BC. Evaluation of endogenous steroids profile after administration of anabolic steroid. J Kor Chem Soc 1997; 41: 406-13 |
22 | Porter KB, Tsibris JCM, Porter G, Fuchs-young R, Nicosia SV, O'Brien WF, pellacy WN. Effect of raloxifene in a guinea pig model for leiomyomas. Gynecology 1998; 179: 1283-7 |
![]() |